We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

200 hedge funds and large institutions have $3.48B invested in Pacira BioSciences in 2014 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 77 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $20.6M | Put options by funds: $12.9M

5% less repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 77

4% less funds holding

Funds holding: 208 → 200 (-8)

8% less capital invested

Capital invested by funds: $3.76B → $3.48B (-$285M)

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

56% less funds holding in top 10

Funds holding in top 10: 9 → 4 (-5)

Holders
200
Holders Change
-8
Holders Change %
-3.85%
% of All Funds
5.33%
Holding in Top 10
4
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-55.56%
% of All Funds
0.11%
New
32
Increased
73
Reduced
77
Closed
36
Calls
$20.6M
Puts
$12.9M
Net Calls
+$7.64M
Net Calls Change
+$12.6M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$56.6M
2
Invesco
Invesco
Georgia
+$44.1M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$37.5M
4
MCMC
Matrix Capital Management Company
New Hampshire
+$33.1M
5
American Century Companies
American Century Companies
Missouri
+$29.1M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$71.2M
2
1832 Asset Management
1832 Asset Management
Ontario, Canada
-$59.9M
3
CCI
Columbus Circle Investors
-$40.6M
4
Two Sigma Investments
Two Sigma Investments
New York
-$22.2M
5
NCGI
Next Century Growth Investors
Minnesota
-$19.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
151
Rafferty Asset Management
New York
$473K +$504K +5,331 New
NIT
152
NumerixS Investment Technologies
British Columbia, Canada
$461K +$492K +5,200 New
SEI Investments
153
SEI Investments
Pennsylvania
$452K +$482K +5,100 New
PC
154
Polar Capital
United Kingdom
$451K +$481K +5,087 New
ZIM
155
Zacks Investment Management
Illinois
$433K +$462K +4,885 New
Fisher Asset Management
156
Fisher Asset Management
Washington
$426K +$454K +4,800 New
PA
157
Profund Advisors
Maryland
$407K +$26.2K +277 +6%
FMT
158
First Mercantile Trust
Tennessee
$395K -$1.03M -10,845 -71%
Jane Street
159
Jane Street
New York
$376K -$354K -3,739 -47%
DC
160
Deere & Company
Illinois
$369K – – –
Prudential Financial
161
Prudential Financial
New Jersey
$350K – – –
US Bancorp
162
US Bancorp
Minnesota
$345K +$229K +2,425 +166%
CSS
163
Cubist Systematic Strategies
Connecticut
$337K +$280K +2,961 +354%
BCM
164
Bienville Capital Management
New York
$310K +$331K +3,500 New
AB
165
Amalgamated Bank
New York
$309K +$378 +4 +0.1%
Janney Montgomery Scott
166
Janney Montgomery Scott
Pennsylvania
$306K -$4.73K -50 -1%
QT
167
Quantbot Technologies
New York
$302K -$87.4K -924 -21%
SMG
168
Spectrum Management Group
Indiana
$284K -$8.51K -90 -3%
AIP
169
Ameritas Investment Partners
Nebraska
$283K – – –
SCM
170
Sterling Capital Management
North Carolina
$261K +$7.47K +79 +3%
JMPWA
171
JP Morgan Private Wealth Advisors
California
$227K – – –
HSBC Holdings
172
HSBC Holdings
United Kingdom
$226K +$241K +2,553 New
Canada Life
173
Canada Life
Manitoba, Canada
$224K – – –
Commonwealth Equity Services
174
Commonwealth Equity Services
Massachusetts
$216K – – –
MAM
175
Martingale Asset Management
Massachusetts
$213K -$549K -5,802 -71%
5 6
7
8 9

PCRX Hedge Fund Activity: Q4 2014 in Review

200 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2014, worth a combined $3.48B — down 7.6% from $3.76B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of PCRX and 32 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 73 added.

The largest buyer was Jennison Associates, adding an estimated $56.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $71.2M.

  • 200 institutional investors held Pacira BioSciences (PCRX) as of Q4 2014, down from 208 in Q3 2014.
  • Funds reported $3.48B of Pacira BioSciences stock for Q4 2014, down 7.6% quarter-over-quarter.
  • 32 funds opened new Pacira BioSciences positions in Q4 2014 and 36 closed out, a net change of -4 holders.
  • The largest Pacira BioSciences buyer in Q4 2014 was Jennison Associates, an estimated $56.6M added.
  • The largest Pacira BioSciences seller in Q4 2014 was T. Rowe Price Associates, an estimated $71.2M sold.

Based on aggregated 13F filings for Q4 2014.